Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Mar
27
Evolving Expectations in Immunologic Disease: Our work with those living with immune-mediated diseases and HCPs
Mar
27
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Mar
27
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
Mar
24
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
Mar
16
3 in 3: Advancing hope for rare and ultra-rare disease communities, one innovation at a time
Mar
11
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
Mar
10
Innovation Equals Access: How UCB Delivered for Patients in 2025
Feb
04
More than Medicine: UCB's Holistic Approach to Supporting MG Patients
Dec
08
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder